
Opinion|Videos|January 31, 2025
Faricimab Molecular Design and Role of Ang-2
Panelists discuss how faricimab’s bispecific antibody design uniquely targets both VEGF-A and Ang-2 pathways, addressing the complementary role of Ang-2 in vascular destabilization and inflammation in retinal diseases.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is the unique nature of the faricimab molecule, and what is the clinical rationale for targeting Ang-2 in treating retinal diseases?
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Pipeline update: Catch up on recent updates in the retina pipeline
2
Geographic Atrophy in AMD and nAMD Patients: Real-World Management Challenges and Strategies
3
AAO 2025: The safety and efficacy of oral gildeuretinol in participants with intermediate-stage Stargardt disease
4
















































